SCHEMBL3620828

SCHEMBL3620828

O=C(O)Cc1csc(NS(=O)(=O)c2ccc(Cl)cc2)n1

nearest known ligand 0.71

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.71
KDM1A O60341 7/20 0.59
ALDH1A1 P00352 2/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
MEN1 O00255 5/20 0.56
PKM P14618 1/20 0.55
MAOA P21397 2/20 0.53
GAA P10253 2/20 0.53
MAPT P10636 1/20 0.53
POLB P06746 2/20 0.53
CTPS1 P17812 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3619367 0.88 ALDH1A1 (0.72) KMT2AKDM1AALDH1A1CYP2C9CYP2C19
SCHEMBL3623267 0.87 KMT2A (0.56) KMT2AKDM1AALDH1A1CYP2C9CYP2C19
SCHEMBL20472316 0.87 ALDH1A1 (0.58) KMT2AALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL5692691 0.87 ALDH1A1 (0.58) KMT2AKDM1AALDH1A1CYP2C9CYP2C19
SCHEMBL3621458 0.87 ALDH1A1 (0.58) KMT2AKDM1AALDH1A1CYP2C9CYP2C19
SCHEMBL3619275 0.87 ALDH1A1 (0.64) KMT2AKDM1AALDH1A1CYP2C9CYP2C19
SCHEMBL3620162 0.87 ALDH1A1 (0.61) KMT2AALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL3612445 0.87 KMT2A (0.71) KMT2AALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL3611323 0.86 KMT2A (0.55) KMT2AALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL3618440 0.86 ALDH1A1 (0.67) KMT2AALDH1A1CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3300/4885KDM1A 1361/4885ALDH1A1 55/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 KMT2A 3769/4885KDM1A 1569/4885ALDH1A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.